Literature DB >> 19796663

Influence of DRD2 and ANKK1 genotypes on apomorphine-induced growth hormone (GH) response in alcohol-dependent patients.

Michael Lucht1, Agnieszka Samochowiec, Jerzy Samochowiec, Andrzej Jasiewicz, Hans Joergen Grabe, Ingrid Geissler, Christian Rimmbach, Dieter Rosskopf, Anna Grzywacz, Justyna Pełka Wysiecka, Piotr Tybura, Bogusław Brzuchalski, Przemysław Bieńkowski.   

Abstract

BACKGROUND: D(2) receptor function can be assessed by growth hormone (GH) response to apomorphine. Several association studies between dopamine receptor polymorphisms and results of the apomorphine challenge test with normal and alcohol-dependent subjects yielded inconsistent results. In this pilot study, we tested polymorphisms from the DRD2 region for GH response to apomorphine challenge in more detail.
METHODS: Apomorphine challenge tests measuring GH responses on 5 time points were performed on day 1 of alcohol detoxification in 43 patients with alcohol dependence; patients were genotyped for 11 polymorphisms including DRD2, ANKK1, NCAM1 and TTC12.
RESULTS: Associations (p<0.05) were found for ANKK1 (rs11604671, rs1800497) and DRD2 (rs6276, rs1076560), which are located on adjacent chromosomal positions. Consistent with PET studies suggesting a reduced D(2) receptor availability in patients carrying the ANKK1 rs1800497 T polymorphism (formerly known as DRD2 TaqI A1) we found a reduced GH response to apomorphine in those subjects.
CONCLUSION: This has been the first study showing significant associations between apomorphine-induced GH response and SNPs in DRD2 and ANKK1 in alcohol-dependent patients. In this respect, our preliminary results are in line with other reports which suggested that DRD2 and ANKK1 polymorphisms influence D(2) receptor availability and signal transduction in the dopaminergic pathways. Small sample size in our study limits the generalizability of our results. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19796663     DOI: 10.1016/j.pnpbp.2009.08.024

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  11 in total

1.  A high-coverage genome sequence from an archaic Denisovan individual.

Authors:  Matthias Meyer; Martin Kircher; Marie-Theres Gansauge; Heng Li; Fernando Racimo; Swapan Mallick; Joshua G Schraiber; Flora Jay; Kay Prüfer; Cesare de Filippo; Peter H Sudmant; Can Alkan; Qiaomei Fu; Ron Do; Nadin Rohland; Arti Tandon; Michael Siebauer; Richard E Green; Katarzyna Bryc; Adrian W Briggs; Udo Stenzel; Jesse Dabney; Jay Shendure; Jacob Kitzman; Michael F Hammer; Michael V Shunkov; Anatoli P Derevianko; Nick Patterson; Aida M Andrés; Evan E Eichler; Montgomery Slatkin; David Reich; Janet Kelso; Svante Pääbo
Journal:  Science       Date:  2012-08-30       Impact factor: 47.728

2.  Altered regional brain volumes in elderly carriers of a risk variant for drug abuse in the dopamine D2 receptor gene (DRD2).

Authors:  Florence F Roussotte; Neda Jahanshad; Derrek P Hibar; Paul M Thompson
Journal:  Brain Imaging Behav       Date:  2015-06       Impact factor: 3.978

3.  The dopamine receptor D2 (DRD2) SNP rs1076560 is associated with opioid addiction.

Authors:  Toni-Kim Clarke; Amy R D Weiss; Thomas N Ferarro; Kyle M Kampman; Charles A Dackis; Helen M Pettinati; Charles P O'brien; David W Oslin; Falk W Lohoff; Wade H Berrettini
Journal:  Ann Hum Genet       Date:  2013-11-25       Impact factor: 1.670

4.  Association study of candidate gene polymorphisms and obesity in a young Mexican-American population from South Texas.

Authors:  Jorge Duran-Gonzalez; Ixiu Ortiz; Enrique Gonzales; Nicole Ruiz; Manti Ortiz; Arthur Gonzalez; Edna K Sanchez; Eugenia Curet; Susan Fisher-Hoch; Anne Rentfro; Huiqi Qu; Saraswathy Nair
Journal:  Arch Med Res       Date:  2011-11-01       Impact factor: 2.235

5.  Updated findings of the association and functional studies of DRD2/ANKK1 variants with addictions.

Authors:  Yunlong Ma; Wenji Yuan; Xianzhong Jiang; Wen-Yan Cui; Ming D Li
Journal:  Mol Neurobiol       Date:  2014-08-20       Impact factor: 5.590

6.  Genetic Polymorphisms in the Dopamine Receptor 2 Predict Acute Pain Severity After Motor Vehicle Collision.

Authors:  Yawar J Qadri; Andrey V Bortsov; Danielle C Orrey; Robert A Swor; David A Peak; Jeffrey S Jones; Niels K Rathlev; David C Lee; Robert M Domeier; Phyllis L Hendry; Samuel A Mclean
Journal:  Clin J Pain       Date:  2015-09       Impact factor: 3.442

7.  The ANKK1 protein associated with addictions has nuclear and cytoplasmic localization and shows a differential response of Ala239Thr to apomorphine.

Authors:  E Garrido; T Palomo; G Ponce; I García-Consuegra; M A Jiménez-Arriero; J Hoenicka
Journal:  Neurotox Res       Date:  2010-09-16       Impact factor: 3.911

8.  Intronic polymorphisms affecting alternative splicing of human dopamine D2 receptor are associated with cocaine abuse.

Authors:  Robert A Moyer; Danxin Wang; Audrey C Papp; Ryan M Smith; Linda Duque; Deborah C Mash; Wolfgang Sadee
Journal:  Neuropsychopharmacology       Date:  2010-12-08       Impact factor: 7.853

9.  ANKK1, TTC12, and NCAM1 polymorphisms and heroin dependence: importance of considering drug exposure.

Authors:  Elliot C Nelson; Michael T Lynskey; Andrew C Heath; Naomi Wray; Arpana Agrawal; Fiona L Shand; Anjali K Henders; Leanne Wallace; Alexandre A Todorov; Andrew J Schrage; Nancy L Saccone; Pamela A F Madden; Louisa Degenhardt; Nicholas G Martin; Grant W Montgomery
Journal:  JAMA Psychiatry       Date:  2013-03       Impact factor: 21.596

10.  A two-locus genetic interaction between LPHN3 and 11q predicts ADHD severity and long-term outcome.

Authors:  M T Acosta; J I Vélez; M L Bustamante; J Z Balog; M Arcos-Burgos; M Muenke
Journal:  Transl Psychiatry       Date:  2011-07-05       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.